Very rapid effect of pitavastatin on microvascular function in comparison to rosuvastatin: reactive hyperemia peripheral arterial tonometric study

Figures & data

Table 1 Clinical characteristics of the pitavastatin, rosuvastatin, and control groups

	Pitavastatin (n = 36)	Rosuvastatin (n = 38)	Control (n = 20)	P-value
Age, years	68 ± 12	63 ± 12	70 ± 11	0.08
Sex (male), n (%)	30 (83%)	29 (76%)	14 (70%)	0.5
Hypertension, n (%)	27 (75%)	31 (82%)	17 (85%)	0.6
Hyperlipidemia, n (%)	19 (53%)	20 (53%)	7 (35%)	0.4
Diabetes, n (%)	17 (47%)	18 (47%)	8 (40%)	0.8
Body mass index, kg/m^2	23.6 ± 3.9	23.2 ± 4.1	22.8 ± 4.6	0.5
Previous history of MI, n (%)	8 (22%)	8 (22%)	5 (25%)	0.9
Previous history of coronary revascularization, n (%)	20 (56%)	15 (39%)	11 (55%)	0.3
Medication
Beta-blockers, n (%)	10 (28%)	9 (24%)	5 (25%)	0.9
Calcium channel blockers, n (%)	20 (56%)	13 (34%)	8 (40%)	0.2
ACEI or ARB, n (%)	22 (61%)	28 (74%)	12 (60%)	0.4
Aspirin, n (%)	24 (67%)	22 (58%)	11 (55%)	0.6

Note: Values are mean ± SD.

Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blockers; MI, myocardial infarction.

Figure 1 Baseline RH-PAT index and medications.

Notes: Values are expressed as mean (standard deviation). P-values showed the results of the comparison of RH-PAT index before and after treatment in each medication.
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; RH-PAT, reactive hyperemia peripheral arterial tonometry.

Figure 2 RH-PAT index before and after treatment in the pitavastatin group (left), rosuvastatin group (middle), and control group (right).

Notes: Values are expressed as means (standard deviation). P-values represent the results of one-way analysis of variance before and after treatment, respectively. *denotes P < 0.05 versus the corresponding parameter before treatment.
Abbreviations: CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; RH-PAT, reactive hyperemia peripheral arterial tonometry.